China’s WuXi Pharma Tech Shakes Up Its Board After Tumultuous Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The West's financial morass could ultimately prod the world's pharmaceutical giants to outsource more research and development to lower-cost China, and to WuXi PharmaTech, CEO says.
You may also be interested in...
WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec
BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees
WuXi Reports Expanded Research Deal With J&J And Higher Profits, But Also Sharper Risks Sparked By Global Financial Crisis
BEIJING - WuXi PharmaTech reported strong earnings growth for the third quarter, but also cautioned that the financial crisis sweeping across the globe would cut into profits for the whole of 2008
Covance, WuXi Abandon Plans To Create Joint Drug Testing Facility In China
BEIJING - Just three months after unveiling plans to create a joint venture facility for preclinical drug testing services on China's east coast, the Shanghai-headquartered WuXi PharmaTech and and Princeton, N.J.-based Covance have called off the deal